Upadacitinib in Asian inflammatory bowel disease practice: encouraging real-world efficacy

July 29, 2026Intestinal ResearchOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

Evaluate the real-world efficacy of upadacitinib in patients with inflammatory bowel disease who have failed multiple biologic therapies.
Observational study of biologic-experienced patients with inflammatory bowel disease at tertiary referral centers.
Emphasized collection of symptom-based patient-reported outcomes (PROs).
Assessed changes in diarrhea frequency, abdominal pain, and other symptoms contrary to traditional metrics.
Observed high remission rates, which should be interpreted cautiously due to variability in endpoint definitions.
Notable improvements in symptom relief, particularly in diarrhea frequency and abdominal pain were reported.
Efficacy retained even in patients with a history of multiple biologic failures.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Real-world efficacy of upadacitinib shows meaningful symptom relief in patients with advanced IBD therapies, indicating its potential.

No takes yet. Share an insight, caveat, or question.

Eun Soo Kim (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share